Silence Therapeutics PLC CRISPR/Cas9 Gene Editing Data (1506P)

TIDMSLN

RNS Number : 1506P

Silence Therapeutics PLC

15 November 2016

CRISPR/Cas9 Gene Editing Data

A single-particle RNA based approach to in vivo CRISPR/Cas9 gene editing

London, 15 November 2016 - Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, is pleased to announce significant in vivo CRISPR/Cas9 gene editing data. These data will be presented at the EuroTIDES 2016 meeting in Berlin, Germany.

Using its proprietary liver targeted lipid nanoparticle (LNP) to deliver the CRISPR/Cas9 components, Silence has confirmed the potential of its delivery platform for in vivo gene editing:

-- Sustained down-regulation of two independent secreted liver gene products in blood serum was observed for over 200 days

   --     Serum levels of TTR protein were reduced by approximately 70% 

-- In the cross-controlled experimental cohort, serum levels of PCSK9 protein were reduced by approximately 55%

-- Target levels in the groups treated with a guide RNA (gRNA) directed to a different gene were comparable to those of untreated animals

Ali Mortazavi, Chief Executive Officer of Silence Therapeutics, commented:

"As in RNA interference, efficient payload delivery is critical in gene editing. We have leveraged our experience in RNA delivery systems to demonstrate that our LNP can be used for CRISPR/Cas9 applications. The pre-clinical biological activity that we have observed supports future in vivo clinical applications in the gene editing space, which was initially thought to be limited to ex vivo interventions. We have shown that our LNPs are suitable for the delivery of large cargos such as RNA CRISPR/Cas9 components, and we are discussing collaborations in this area with potential partners."

Study details

The present experiment was designed as a preliminary proof-of-concept for the use of our optimised LNPs to co-deliver mRNA encoding Cas9 and gRNA targeting either the mouse TTR or PCSK9 genes. In vivo activity through gene-specific DNA disruption in mouse liver was measured by quantification of corresponding proteins in serum. Upon completion of the study, further data will become available.

Notes to Editors

About Silence Therapeutics plc

Our RNA-based technologies harness the body's natural mechanisms to create therapeutic effects within its cells. These technologies can selectively silence or replace any gene in the genome, modulating gene expression up as well as down in a variety of organs and cell types, in vivo. We have developed proprietary modifications to improve the robustness of RNA molecules, as well as advanced chemistries to enhance the effective delivery of therapeutic RNA molecules to target cells.

Enquiries:

 
 Silence Therapeutics plc                            Tel: +44 (0)20 
  Ali Mortazavi, Chief Executive                          3457 6900 
  Officer 
  David Ellam, Chief Financial Officer 
 Canaccord Genuity Limited (Nominated                Tel: +44 (0)20 
  Adviser and Joint Broker)                               7523 8350 
  Dr Julian Feneley/Henry Fitzgerald-O'Connor/Emma 
  Gabriel 
 Peel Hunt LLP (Joint Broker)                        Tel: +44 (0)20 
  James Steel/Oliver Jackson                              7418 8900 
 Media Enquiries:                                      Tel: +44 (0) 
  FTI Consulting                                       20 3727 1000 
  Simon Conway/Brett Pollard/Stephanie 
  Cuthbert 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCEAPFLFAFKFFF

(END) Dow Jones Newswires

November 15, 2016 02:00 ET (07:00 GMT)